Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134218) titled 'Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Changhai Hospital
Condition:
Rectal Cancer
Intervention:
Drug: serplulimab?bevacizumab
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: October 2025
Target Sample Size: 180
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/sh...